These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 16780958

  • 21. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

  • 22. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D.
    J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
    [Abstract] [Full Text] [Related]

  • 23. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
    Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD.
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [Abstract] [Full Text] [Related]

  • 25. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A.
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
    Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M.
    Depress Anxiety; 2006 May; 23(3):178-81. PubMed ID: 16528701
    [Abstract] [Full Text] [Related]

  • 30. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS, Loft H, Dragheim M.
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
    [Abstract] [Full Text] [Related]

  • 31. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 32. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D.
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [Abstract] [Full Text] [Related]

  • 33. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials.
    Hall JA, Wang F, Oakes TM, Utterback BG, Crucitti A, Acharya N.
    Expert Opin Drug Saf; 2010 Jul; 9(4):525-37. PubMed ID: 20465525
    [Abstract] [Full Text] [Related]

  • 34. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS, Reines EH, Guiton C, Weiller E.
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [Abstract] [Full Text] [Related]

  • 35. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
    Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA.
    Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Time course of depression-symptom improvement during treatment with duloxetine.
    Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ.
    Depress Anxiety; 2005 Nov; 21(4):170-7. PubMed ID: 16035056
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN.
    Depress Anxiety; 2008 Nov; 25(7):E1-11. PubMed ID: 17587217
    [Abstract] [Full Text] [Related]

  • 39. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.